Tags

Type your tag names separated by a space and hit enter

Encephalitozoon cuniculi Genotype III Evinces a Resistance to Albendazole Treatment in both Immunodeficient and Immunocompetent Mice.
Antimicrob Agents Chemother. 2020 04 21; 64(5)AA

Abstract

Of four genotypes of Encephalitozoon cuniculi, E. cuniculi genotype II is considered to represent a parasite that occurs in many host species in a latent asymptomatic form, whereas E. cuniculi genotype III seems to be more aggressive, and infections caused by this strain can lead to the death of even immunocompetent hosts. Although albendazole has been considered suitable for treatment of Encephalitozoon species, its failure in control of E. cuniculi genotype III infection has been reported. This study determined the effect of a 100× recommended daily dose of albendazole on an Encephalitozoon cuniculi genotype III course of infection in immunocompetent and immunodeficient mice and compared the results with those from experiments performed with a lower dose of albendazole and E. cuniculi genotype II. The administration of the regular dose of abendazole during the acute phase of infection reduced the number of affected organs in all strains of mice and absolute counts of spores in screened organs. However, the effect on genotype III was minor. Surprisingly, no substantial effect was recorded after the use of a 100× dose of albendazole, with larger reductions seen only in the number of affected organs and absolute counts of spores in all strains of mice, implying variations in albendazole resistance between these Encephalitozoon cuniculi genotypes. These results imply that differences in the course of infection and the response to treatment depend not only on the immunological status of the host but also on the genotype causing the infection. Understanding how microsporidia survive in hosts despite targeted antimicrosporidial treatment could significantly contribute to research related to human health.

Authors+Show Affiliations

Institute of Parasitology, Biology Centre, Czech Academy of Science, České Budějovice, Czech Republic casio@paru.cas.cz.Faculty of Science, University of South Bohemia in České Budějovice, České Budějovice, Czech Republic.Institute of Parasitology, Biology Centre, Czech Academy of Science, České Budějovice, Czech Republic. Faculty of Agriculture, University of South Bohemia in České Budějovice, České Budějovice, Czech Republic.Institute of Parasitology, Biology Centre, Czech Academy of Science, České Budějovice, Czech Republic.Institute of Parasitology, Biology Centre, Czech Academy of Science, České Budějovice, Czech Republic.Institute of Parasitology, Biology Centre, Czech Academy of Science, České Budějovice, Czech Republic. Faculty of Agriculture, University of South Bohemia in České Budějovice, České Budějovice, Czech Republic.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32152088

Citation

Sak, Bohumil, et al. "Encephalitozoon Cuniculi Genotype III Evinces a Resistance to Albendazole Treatment in Both Immunodeficient and Immunocompetent Mice." Antimicrobial Agents and Chemotherapy, vol. 64, no. 5, 2020.
Sak B, Brdíčková K, Holubová N, et al. Encephalitozoon cuniculi Genotype III Evinces a Resistance to Albendazole Treatment in both Immunodeficient and Immunocompetent Mice. Antimicrob Agents Chemother. 2020;64(5).
Sak, B., Brdíčková, K., Holubová, N., Květoňová, D., Hlásková, L., & Kváč, M. (2020). Encephalitozoon cuniculi Genotype III Evinces a Resistance to Albendazole Treatment in both Immunodeficient and Immunocompetent Mice. Antimicrobial Agents and Chemotherapy, 64(5). https://doi.org/10.1128/AAC.00058-20
Sak B, et al. Encephalitozoon Cuniculi Genotype III Evinces a Resistance to Albendazole Treatment in Both Immunodeficient and Immunocompetent Mice. Antimicrob Agents Chemother. 2020 04 21;64(5) PubMed PMID: 32152088.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Encephalitozoon cuniculi Genotype III Evinces a Resistance to Albendazole Treatment in both Immunodeficient and Immunocompetent Mice. AU - Sak,Bohumil, AU - Brdíčková,Klára, AU - Holubová,Nikola, AU - Květoňová,Dana, AU - Hlásková,Lenka, AU - Kváč,Martin, Y1 - 2020/04/21/ PY - 2020/01/09/received PY - 2020/03/04/accepted PY - 2020/10/21/pmc-release PY - 2020/3/11/pubmed PY - 2020/3/11/medline PY - 2020/3/11/entrez KW - Encephalitozoon cuniculi KW - albendazole KW - genotype III KW - microsporidiosis KW - tolerance KW - treatment JF - Antimicrobial agents and chemotherapy JO - Antimicrob. Agents Chemother. VL - 64 IS - 5 N2 - Of four genotypes of Encephalitozoon cuniculi, E. cuniculi genotype II is considered to represent a parasite that occurs in many host species in a latent asymptomatic form, whereas E. cuniculi genotype III seems to be more aggressive, and infections caused by this strain can lead to the death of even immunocompetent hosts. Although albendazole has been considered suitable for treatment of Encephalitozoon species, its failure in control of E. cuniculi genotype III infection has been reported. This study determined the effect of a 100× recommended daily dose of albendazole on an Encephalitozoon cuniculi genotype III course of infection in immunocompetent and immunodeficient mice and compared the results with those from experiments performed with a lower dose of albendazole and E. cuniculi genotype II. The administration of the regular dose of abendazole during the acute phase of infection reduced the number of affected organs in all strains of mice and absolute counts of spores in screened organs. However, the effect on genotype III was minor. Surprisingly, no substantial effect was recorded after the use of a 100× dose of albendazole, with larger reductions seen only in the number of affected organs and absolute counts of spores in all strains of mice, implying variations in albendazole resistance between these Encephalitozoon cuniculi genotypes. These results imply that differences in the course of infection and the response to treatment depend not only on the immunological status of the host but also on the genotype causing the infection. Understanding how microsporidia survive in hosts despite targeted antimicrosporidial treatment could significantly contribute to research related to human health. SN - 1098-6596 UR - https://www.unboundmedicine.com/medline/citation/32152088/Encephalitozoon_cuniculi_Genotype_III_Evinces_a_Resistance_to_Albendazole_Treatment_in_both_Immunodeficient_and_Immunocompetent_Mice_ L2 - http://aac.asm.org/cgi/pmidlookup?view=long&pmid=32152088 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.